Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07364357
A Phase I Study of CREPT-618 in Locally Advanced HCC
An Open-label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of CREPT-618 in Patients With Locally Advanced Hepatocellular Carcinoma
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
gene therapy
Updated 1 time since 2026 Last updated: Jan 15, 2026 Started: Sep 15, 2025 Primary completion: Aug 15, 2026 Completion: Sep 15, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07364357, this PHASE1 trial focuses on Hepatocellular Carcinoma (HCC) and remains actively recruiting participants. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .